ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Several metalloproteases (ADAMs) influence amyloid precursor protein (APP) metabolism.
• The complete set of metalloproteases in APP metabolism is not fully understood.
• Alzheimer's disease (AD) is characterized by amyloid plaque accumulation.

Purpose of the Study:

• To investigate the role of ADAM30 in APP metabolism and its potential link to Alzheimer's disease.
• To determine how ADAM30 expression levels affect amyloid-beta (Aβ) peptide production.

Main Methods:

• Transcriptomic analysis of metalloprotease genes in AD brains.
• In vitro studies involving down-regulation and up-regulation of ADAM30 expression.
• Proteomics and cell-based assays to elucidate ADAM30's mechanism of action.
• Experiments in Alzheimer-like transgenic mice.

Main Results:

• AD brains showed a 50% decrease in ADAM30 expression, inversely correlating with amyloid load.
• Altering ADAM30 expression modulated Aβ peptide levels in vitro.
• ADAM30-dependent APP metabolism requires cathepsin D (CTSD) activation and lysosomal sorting.
• Over-expression of ADAM30 in transgenic mice reduced Aβ42 secretion, amyloid plaque load, and improved cognitive function.

Conclusions:

• Reduced ADAM30 expression may contribute to Alzheimer's disease by increasing Aβ production.
• ADAM30 plays a crucial role in regulating APP metabolism through CTSD activation and lysosomal pathways.
• Modulating ADAM30 activity presents a potential therapeutic strategy for Alzheimer's disease.